Favipiravir
Favipiravir is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
COVID-19
Case Study: COVID-19
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
65 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | 2 | 18 | 23 | 2 | 5 | 43 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Human influenza | D007251 | EFO_0007328 | J11.1 | 1 | 4 | 2 | — | — | 6 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | 2 | 2 | — | — | 3 | |
| Communicable diseases | D003141 | — | — | 1 | — | — | 1 | ||
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | 1 | — | — | 1 |
| Respiratory tract infections | D012141 | J06.9 | — | — | 1 | — | — | 1 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 1 | — | — | 1 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sars-cov-2 | D000086402 | — | 3 | — | — | — | 3 | ||
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | 2 | — | — | — | 2 |
| Ebola hemorrhagic fever | D019142 | EFO_0007243 | A98.4 | — | 2 | — | — | — | 2 |
| Critical illness | D016638 | — | 1 | — | — | — | 1 | ||
| Lassa fever | D007835 | EFO_0007338 | A96.2 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FAVIPIRAVIR |
| INN | favipiravir |
| Description | Favipiravir is a member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan. It has a role as an antiviral drug, an anticoronaviral agent and an EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor. It is a primary carboxamide, a hydroxypyrazine and an organofluorine compound. |
| Classification | Small molecule |
| Drug class | antivirals: treatments of SARS-CoV-2 infection, inhibiting viral RNA replication |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1nc(F)cnc1O |
Identifiers
| PDB | — |
| CAS-ID | 259793-96-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL221722 |
| ChEBI ID | — |
| PubChem CID | 492405 |
| DrugBank | DB12466 |
| UNII ID | EW5GL2X7E0 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,486 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
59,937 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more